# Geron Corporation (GERN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $1.57, market value $1.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Geron Corporation reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.76**. A PEG of 0.76 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 4256.0×**. Each dollar of revenue is priced at 4256.0×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.6×**. The shares trade at 4.6× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -37.0%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -72.4%**. Return on all capital, debt included, is -72.4%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -32.3%**. Each dollar of assets produces -32.3% of profit.

## Growth
- **EPS growth (1 yr): 51.9%**. Earnings per share rose 51.9%.

## Financial health
- **Debt to equity: 0.53**. Debt is 0.53 times equity, moderate leverage.
- **Net debt / EBITDA: net cash**. Geron Corporation holds more cash than debt.
- **Interest coverage: -23.3×**. Operating profit covers interest only -23.3×: fragile.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Geron Corporation does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 13.8%** (YTD 18.9%, 3-mo 34.2%). The shares are up 13.8% over twelve months including dividends.
- **From 52-week high: -21.9%** (51.0% above the low). Trading 22% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 55**. An RSI of 55 is neutral.
- **Beta (1 yr): 1.29** (volatility 64%). Beta of 1.29 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GERN · Page: https://foliofundamentals.com/stocks/gern

Not investment advice.